Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTT2SVW)

• DTT Name: PPAR-gamma messenger RNA (PPARG mRNA) DTT Info
• Gene Name: PPARG

Molecule-Related Drug & Molecule List

1 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bardoxolone methyl	DMODA2X	Mixed connective tissue disease	4A43.3	Phase 3	[1]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AD-5075	DM1SLJ9	Type-2 diabetes	5A11	Terminated	[2]

51 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid	DM2REIN	Discovery agent	N.A.	Investigative	[3]
(E)-10-Nitrohexadec-9-enoic Acid	DMO38CP	Discovery agent	N.A.	Investigative	[3]
(E)-10-nitrooctadec-9-enoic acid	DMTF7JA	Discovery agent	N.A.	Investigative	[3]
(E)-12-Nitrooctadec-12-enoic Acid	DMBQTZL	Discovery agent	N.A.	Investigative	[3]
(E)-13-Nitrooctadec-12-enoic Acid	DMF74GJ	Discovery agent	N.A.	Investigative	[3]
(E)-5-Nitrooctadec-5-enoic Acid	DMJKOFW	Discovery agent	N.A.	Investigative	[3]
(E)-6-Nitrooctadec-5-enoic Acid	DMACVNM	Discovery agent	N.A.	Investigative	[3]
(E)-9-Nitrohexadec-9-enoicAcid	DMULW35	Discovery agent	N.A.	Investigative	[3]
(E)-9-nitrooctadec-9-enoic acid	DMWC2F9	Discovery agent	N.A.	Investigative	[3]
2-chloro-5-nitro-N-phenylbenzamide	DMUGQIV	Discovery agent	N.A.	Investigative	[4]
AD-5061	DM5WV13	Discovery agent	N.A.	Investigative	[5]
BADGE	DMCK5DG	Discovery agent	N.A.	Investigative	[6]
BRL-48482	DMT4NM5	Discovery agent	N.A.	Investigative	[7]
CHLOROCYCLINONE A	DMZA394	Discovery agent	N.A.	Investigative	[8]
CHLOROCYCLINONE B	DMO78QB	Discovery agent	N.A.	Investigative	[8]
CHLOROCYCLINONE C	DMX2DQ5	Discovery agent	N.A.	Investigative	[8]
CHLOROCYCLINONE D	DMK7VS1	Discovery agent	N.A.	Investigative	[8]
COOH	DM5DTZR	Discovery agent	N.A.	Investigative	[9]
DRF 2519	DMTFQG3	Discovery agent	N.A.	Investigative	[10]
GNF-PF-2893	DMLP241	Discovery agent	N.A.	Investigative	[11]
GNF-PF-3037	DM4RZSB	Discovery agent	N.A.	Investigative	[11]
GW0072	DM3D2R4	Discovery agent	N.A.	Investigative	[12]
GW1929	DMOV980	Discovery agent	N.A.	Investigative	[13]
ISIS 105987	DMIGV0H	Discovery agent	N.A.	Investigative	[14]
ISIS 105989	DMFOSYU	Discovery agent	N.A.	Investigative	[14]
ISIS 105990	DM8FY3H	Discovery agent	N.A.	Investigative	[15]
ISIS 106008	DMTY6O9	Discovery agent	N.A.	Investigative	[14]
L-165461	DMKBSGN	Discovery agent	N.A.	Investigative	[16]
L-764406	DMG5KVS	Discovery agent	N.A.	Investigative	[17]
L-783483	DM6OTGE	Discovery agent	N.A.	Investigative	[18]
L-796449	DMWTGQM	Discovery agent	N.A.	Investigative	[16]
L-Tryptophan-L-2-aminoadipic acid	DMYLONS	Discovery agent	N.A.	Investigative	[4]
L-Tryptophan-L-arginine	DMYU65F	Discovery agent	N.A.	Investigative	[4]
L-Tryptophan-L-asparagine	DMWZMCA	Discovery agent	N.A.	Investigative	[4]
L-Tryptophan-L-aspartic acid	DMVFAD5	Discovery agent	N.A.	Investigative	[4]
L-Tryptophan-L-glutamine	DMNMRHX	Discovery agent	N.A.	Investigative	[4]
L-Tryptophan-L-leucine	DMPV5D0	Discovery agent	N.A.	Investigative	[4]
LG100754	DMEK4FY	Discovery agent	N.A.	Investigative	[19]
LY-465608	DMK64AZ	Discovery agent	N.A.	Investigative	[20]
nTzDpa	DMTHB2Y	Discovery agent	N.A.	Investigative	[21]
PAT5A	DMRJ104	Discovery agent	N.A.	Investigative	[22]
PD-068235	DM8QMJ1	Discovery agent	N.A.	Investigative	[4]
Ploglitazone	DM4MKIX	Discovery agent	N.A.	Investigative	[23]
reglitazar	DMQ3ER0	Discovery agent	N.A.	Investigative	[24]
SB-213068	DMUCHNP	Discovery agent	N.A.	Investigative	[7]
T0070907	DMTKSVO	Discovery agent	N.A.	Investigative	[25]
tagitinin A	DM2RN0S	Discovery agent	N.A.	Investigative	[26]
tirotundin	DMQ4GBO	Discovery agent	N.A.	Investigative	[26]
TZD18	DMVCHOX	Discovery agent	N.A.	Investigative	[27]
[125I]SB-236636	DM0XUPK	Discovery agent	N.A.	Investigative	[28]
[3H]GW2331	DMJT6D3	Discovery agent	N.A.	Investigative	[29]

References

• [1] A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol. 2000 Oct;14(10):1550-6.
• [2] Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95.
• [3] Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
• [4] Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
• [5] A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
• [6] A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem. 2000 Jan 21;275(3):1873-7.
• [7] Non thiazolidinedione antihyperglycaemic agents. 2: alpha-Carbon substituted beta-phenylpropanoic acids1, Bioorg. Med. Chem. Lett. 6(17):2127-2130 (1996).
• [8] Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8.
• [9] PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion.Diabetes. 2003 Feb;52(2):291-9.
• [10] Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol. 2004 May 3;491(2-3):195-206.
• [11] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [12] A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6102-6.
• [13] A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes. 1999 Jul;48(7):1415-24.
• [14] US patent application no. 6,159,734, Antisense modulation of peroxisome proliferator-activated receptor gamma expression.
• [15] US patent application no. 7,425,545, Modulation of C-reactive protein expression.
• [16] Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
• [17] L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. J Biol Chem. 1999 Mar 19;274(12):7913-22.
• [18] Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25.
• [19] The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2002 Apr 12;277(15):12503-6.
• [20] Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. J Med Chem. 2001 Jun 21;44(13):2061-4.
• [21] Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol. 2003 Apr;17(4):662-76.
• [22] Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity. Metabolism. 2000 Nov;49(11):1417-23.
• [23] Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. J Med Chem. 2004 Aug 12;47(17):4118-27.
• [24] Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9.
• [25] T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem. 2002 May 31;277(22):19649-57.
• [26] Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2954-8.
• [27] A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8.
• [28] Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998 Feb;284(2):751-9.
• [29] Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4318-23.